DK3897636T3 - Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed - Google Patents

Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed Download PDF

Info

Publication number
DK3897636T3
DK3897636T3 DK19901383.0T DK19901383T DK3897636T3 DK 3897636 T3 DK3897636 T3 DK 3897636T3 DK 19901383 T DK19901383 T DK 19901383T DK 3897636 T3 DK3897636 T3 DK 3897636T3
Authority
DK
Denmark
Prior art keywords
aminophenyl
piperidine
amino
substituted
compositions
Prior art date
Application number
DK19901383.0T
Other languages
Danish (da)
English (en)
Inventor
Massimo Ammirante
Sogoie Bahmanyar
Matthew D Correa
Virginia Grant
Joshua Hansen
Evan J Horn
Timothy S Kercher
Christopher Mayne
Mark A Nagy
Rama Krishna Narla
Surendra Nayak
Stephen Norris
Patrick Papa
Veronique Plantevin-Krenitsky
John J Sapienza
Brandon W Whitefield
Shuichan Su
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of DK3897636T3 publication Critical patent/DK3897636T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK19901383.0T 2018-12-19 2019-12-18 Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed DK3897636T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US201962879900P 2019-07-29 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
DK3897636T3 true DK3897636T3 (da) 2025-01-13

Family

ID=71098067

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19901383.0T DK3897636T3 (da) 2018-12-19 2019-12-18 Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed

Country Status (29)

Country Link
US (3) US11149007B2 (https=)
EP (2) EP4494711A3 (https=)
JP (2) JP7494181B2 (https=)
KR (2) KR20250144505A (https=)
CN (2) CN113453681B (https=)
AU (1) AU2019403207B2 (https=)
BR (1) BR112021011968A2 (https=)
CA (1) CA3124130A1 (https=)
CL (1) CL2021001665A1 (https=)
CO (1) CO2021007973A2 (https=)
DK (1) DK3897636T3 (https=)
ES (1) ES3009308T3 (https=)
FI (1) FI3897636T3 (https=)
HR (1) HRP20250095T1 (https=)
HU (1) HUE070506T2 (https=)
IL (1) IL284223B2 (https=)
LT (1) LT3897636T (https=)
MX (1) MX2021007473A (https=)
MY (1) MY205718A (https=)
PE (1) PE20212247A1 (https=)
PL (1) PL3897636T3 (https=)
PT (1) PT3897636T (https=)
RS (1) RS66556B1 (https=)
SG (1) SG11202106507RA (https=)
SI (1) SI3897636T1 (https=)
SM (1) SMT202500111T1 (https=)
TW (1) TWI820276B (https=)
WO (1) WO2020132014A1 (https=)
ZA (1) ZA202104200B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3897636T3 (pl) * 2018-12-19 2025-04-28 Celgene Corporation Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi
US11325889B2 (en) * 2018-12-19 2022-05-10 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CA3165168A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
PE20231746A1 (es) * 2020-06-24 2023-11-06 Celgene Corp Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022019597A1 (ko) * 2020-07-21 2022-01-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
TWI807697B (zh) * 2021-03-17 2023-07-01 大陸商南京明德新藥研發有限公司 呋喃稠環取代的戊二醯亞胺類化合物
EP4359407A4 (en) * 2021-06-25 2025-04-30 Celgene Corporation CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM
EP4359404A4 (en) * 2021-06-25 2025-06-04 Celgene Corporation Cereblon-binding compounds, compositions thereof and methods of treatment therewith
JP2024526192A (ja) * 2021-06-25 2024-07-17 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024102706A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds
US12496301B2 (en) 2023-12-08 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
US20250346577A1 (en) * 2024-05-07 2025-11-13 Bristol-Myers Squibb Company Processes for the preparation of substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds
WO2025235577A1 (en) * 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
TW200621723A (en) * 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
DK2683694T3 (en) * 2011-03-10 2016-07-18 Suzhou Kintor Pharmaceuticals Inc ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
RS61242B1 (sr) * 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3481394A1 (en) * 2016-07-08 2019-05-15 Janssen Pharmaceutica N.V. Thiohydantoin androgen receptor antagonists for the treatment of cancer
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
CA3042301A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
DK3524603T3 (da) 2016-12-19 2022-07-04 Abbisko Therapeutics Co Ltd Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
ES2959954T3 (es) 2017-11-28 2024-02-29 Aarti Pharmalabs Ltd Proceso para la preparación de enzalutamida utilizando un nuevo intermedio
CN111163638B (zh) 2017-12-05 2023-07-25 美国陶氏益农公司 杀有害生物组合物和方法
CA3101227A1 (en) 2018-05-30 2019-12-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式(viii)的恩杂鲁胺的制备方法
PL3897636T3 (pl) * 2018-12-19 2025-04-28 Celgene Corporation Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi
US11325889B2 (en) * 2018-12-19 2022-05-10 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CN119219606A (zh) 2024-12-31
HUE070506T2 (hu) 2025-06-28
EP4494711A2 (en) 2025-01-22
KR102866144B1 (ko) 2025-09-30
NZ777281A (en) 2025-07-25
EP3897636A4 (en) 2022-09-07
MX2021007473A (es) 2021-08-05
CN113453681A (zh) 2021-09-28
EP4494711A3 (en) 2025-05-21
SG11202106507RA (en) 2021-07-29
LT3897636T (lt) 2025-03-25
BR112021011968A2 (pt) 2021-09-08
JP2024109765A (ja) 2024-08-14
FI3897636T3 (fi) 2025-02-03
AU2019403207A1 (en) 2021-07-15
IL284223B2 (en) 2025-08-01
PE20212247A1 (es) 2021-11-24
WO2020132014A1 (en) 2020-06-25
TW202039435A (zh) 2020-11-01
US20240368083A1 (en) 2024-11-07
US11873283B2 (en) 2024-01-16
TWI820276B (zh) 2023-11-01
PT3897636T (pt) 2025-01-27
US11149007B2 (en) 2021-10-19
US12404241B2 (en) 2025-09-02
ES3009308T3 (en) 2025-03-26
JP7724911B2 (ja) 2025-08-18
IL284223A (en) 2021-08-31
CO2021007973A2 (es) 2021-09-09
SI3897636T1 (sl) 2025-04-30
US20200199073A1 (en) 2020-06-25
KR20210118816A (ko) 2021-10-01
MY205718A (en) 2024-11-07
HRP20250095T1 (hr) 2025-04-11
CL2021001665A1 (es) 2022-01-14
EP3897636B1 (en) 2024-12-11
PL3897636T3 (pl) 2025-04-28
CA3124130A1 (en) 2020-06-25
CN113453681B (zh) 2024-10-11
AU2019403207B2 (en) 2025-06-05
SMT202500111T1 (it) 2025-05-12
US20230002321A1 (en) 2023-01-05
KR20250144505A (ko) 2025-10-10
JP7494181B2 (ja) 2024-06-03
ZA202104200B (en) 2024-11-27
RS66556B1 (sr) 2025-03-31
EP3897636A1 (en) 2021-10-27
JP2022514344A (ja) 2022-02-10
IL284223B1 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
DK3897636T3 (da) Substituerede 3-((3-aminophenyl)amino)piperidin-2,6-dionforbindelser, sammensætninger heraf og fremgangsmåde til behandling hermed
SG11202106506WA (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
DK4075992T3 (da) Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf
DK3672949T3 (da) 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivater og anvendelser deraf
DK3943491T3 (da) Heteroarylderivat, fremgangsmåde til fremstilling af samme og farmaceutisk sammensætning indeholdende samme som effektiv komponent
DK4053118T3 (da) Substitueret heterocyklisk kondenseret cyklisk forbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3555070T3 (da) Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf
DK4126066T3 (da) Sammensætninger og fremgangsmåder til behandling af muskeldystrofi
EP4018836C0 (en) COCOA ALKALINIZATION PROCESS
DK3921097T3 (da) Maskine til bearbejdning af stænger og tilsvarende bearbejdningsfremgangsmåde
DK3737423T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindelidelser
DK3952858T3 (da) Fremgangsmåde til behandling af tumorer
EP4045531A4 (en) Methods and compositions comprising modified fab scaffolds and protein g fab binding domains
DK4223886T3 (da) Sammensætninger og fremgangsmåder til stabilisering af mikro-rna
DK3760633T3 (da) Oxazino-quinazolin og oxazino-quinazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf
DK3144617T3 (da) Fremgangsmåde og anordning til tørring af træflis
PL4021171T3 (pl) Metoda związana z działaniem popychacza paszy i popychacz paszy
EP4065725C0 (en) METHODS, COMPOSITIONS AND SYSTEMS FOR ENHANCING THE BINDING OF METHYLATED POLYNUCLEOTIDES
DK3953348T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3510070T3 (da) Fremgangsmåde og sammensætninger til polyurethan-dispersioner, der bruger caprolactam-afledte opløsningsmidler
DK3456712T3 (da) Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP4615453A4 (en) POLYTHERAPY WITH SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS
KR102245308B9 (ko) 클링커 조성물 및 이의 제조방법
DK4069278T3 (da) Fremgangsmåder og sammensætninger til forebyggelse af type 1-diabetes
PT4587429T (pt) Compostos de oxoisoindolinil piperidina-2,6-diona substituídos